Treatment with lornoxicam 4 mg twice daily for 14 d did not produce any change in salivary antipyrine elimination in 11 of 12 healthy volunteers. Anomalous results in one subject are presented and discussed.
Get full access to this article
View all access options for this article.
References
1.
Ankier SI, Brimelow AE, Crome P. et al. Chlortenoxicam pharmacokinetics in young and elderly human volunteers . Postgraduate Medical Journal1988; 64: 752-4.
2.
Ravic M., Johnston A. & Turner P.Clinical pharmacological studies of some possible interactions of lornoxicam with other drugs. Postgraduate Medical Journal1990; 66 (Suppl. 4): S30-4.
3.
Lindgren S., Collste P., Norlander B. & Sjoquist F.Gas chromatographic assessment of the reproducibility of phenazone plasma half-lives in young healthy volunteers. European Journal ofClinical Pharmacology1974; 7: 381-5.
4.
Johnston A. & Wooland RCSTRIPE: an interactive computer programme for the analysis of drug pharmacokinetics . Journal of Pharmacological Methods1983; 9: 193-200.
5.
Fraser HS, Mucklow JC, Murray S. & Davies DSAssessment of antipyrine kinetics by measurement of saliva. British Journal of Clinical Pharmacology1976; 3: 321-5.
6.
Stevenson IHFactors influencing antipyrine eliminaiton. British Journal of Clinical Pharmacology1977; 4: 261-5.
7.
Hedges A., Warrington SJ, Turner P. & Niebch G.Flupirtine maleate and antipyrine half-life. European Journal of Clinical Pharmacology1987; 33: 437.
8.
Johnston A., Warrington SJ, Turner P. & Aurich R.The effect of repeated oral doses of azelastine hydrochloride on antipyrine half-life in normal volunteers. Journal of Pharmacy and Pharmacology1988; 40: 225.
9.
Hitzenberger G., Radhofer-Welte S., Takacs F. & Rosenow D.Pharmacokinetics of lornoxicam in man. Postgraduate Medical Journal1990; 66 (Suppl. 4): S22-6.
10.
Ravic M., Johnston A., Turner P. & Ferber HPA study of the interaction between lornoxicam and warfarin in healthy volunteers . Human and Experimental Toxicology1990; 9, 413-14.
